Mar 5, 2026 07:30AM
Feb 26, 2026 07:00AM
Feb 26, 2026 07:00AM
Feb 26, 2026 07:00AM
Feb 25, 2026 01:20PM
Feb 25, 2026 07:00AM
Feb 4, 2026 07:30AM BIOGEN publishes study results for high-dose nusinersen in Nature Medicine
Feb 4, 2026 07:30AM
Jan 21, 2026 07:00AM
Jan 21, 2026 07:00AM
Jan 12, 2026 11:06AM
Jan 12, 2026 11:05AM
Jan 12, 2026 07:00AM
Jan 7, 2026 02:15AM GSK hepatitis B drug meets goals in phase 3 trials
Jan 7, 2026 02:15AM
Dec 2, 2025 07:00AM
Dec 2, 2025 07:00AM
Dec 1, 2025 07:01AM
Dec 1, 2025 07:00AM
Nov 17, 2025 06:02AM
Nov 17, 2025 06:00AM High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
Nov 14, 2025 04:05PM
Nov 14, 2025 04:05PM
Nov 14, 2025 07:01AM
Nov 14, 2025 07:00AM
Nov 10, 2025 07:30AM
Nov 8, 2025 09:40AM
Nov 6, 2025 08:02AM Ionis presents long-term DAWNZERA data at ACAAI meeting
Nov 6, 2025 08:00AM
Oct 29, 2025 07:00AM
Oct 27, 2025 07:00AM
Oct 21, 2025 08:00AM
Oct 7, 2025 07:03AM
Oct 7, 2025 07:00AM
Sep 23, 2025 04:30PM FDA requests technical updates for Biogen's high dose nusinersen application
Sep 23, 2025 04:30PM
Sep 23, 2025 06:35AM
Sep 22, 2025 07:00AM
Sep 22, 2025 07:00AM
Sep 18, 2025 07:40AM
Sep 18, 2025 07:40AM
Sep 9, 2025 07:00AM Ionis receives FDA breakthrough therapy designation for ION582
Sep 9, 2025 07:00AM
Sep 2, 2025 07:01AM
Sep 2, 2025 07:00AM
Aug 22, 2025 07:37AM
Aug 21, 2025 02:29PM
Aug 21, 2025 12:51PM
Aug 21, 2025 11:45AM DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema
Jul 30, 2025 07:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All